SciBase Holding Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Pia Renaudin

Algemeen directeur

SEK 648.0k

Totale compensatie

Percentage CEO-salaris	77.8%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	9.8yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Pia Renaudin's beloning veranderd ten opzichte van SciBase Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 59m
Mar 31 2024	n/a	n/a	-SEK 56m
Dec 31 2023	SEK 648k	SEK 504k	-SEK 56m

Compensatie versus markt: De totale vergoeding ($USD 60.42K ) Pia } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 243.31K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Pia te vergelijken met de prestaties van het bedrijf.

CEO

Pia Renaudin (57 yo)

1.1yrs

Tenure

SEK 648,000

Compensatie

Ms. Pia Renaudin serves as Chief Executive Officer at SciBase Holding AB (publ) since October 01, 2023 SciBaseHe served as Chief Executive Officer at Senzime AB (publ) since February 08, 2019 until May 03,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pia Renaudin	Chief Executive Officer	1.1yrs	SEK 648.00k	geen gegevens
Stig Ollmar	Founder & Chief Scientific Officer	26.8yrs	geen gegevens	geen gegevens
Michael Colérus	Chief Financial Officer	10.8yrs	SEK 272.54k	geen gegevens
Per Svedenhag	Head of Business Development & Marketing	9.8yrs	SEK 1.43m	geen gegevens
Tobias Bergenblad	Global Sales Director	9.8yrs	geen gegevens	geen gegevens
Leda Beaty	Head of US Commercial Operations	less than a year	geen gegevens	geen gegevens

9.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SCIB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Taapken	Independent Director	7.5yrs	SEK 150.00k	geen gegevens
Matt Leavitt	Independent Director	3.5yrs	SEK 150.00k	geen gegevens
Per Nordberg	Deputy Director	7.8yrs	geen gegevens	geen gegevens
Jesper Hoiland	Chairman of the Board	less than a year	geen gegevens	geen gegevens
Allan Halpern	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Scott Menzies	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Diana Ferro	Independent Director	7.5yrs	SEK 150.00k	geen gegevens
David Elder	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Josep Malvehy	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Holger Hänßle	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Robert Molander	Director	less than a year	geen gegevens	geen gegevens
Jvalini Dwarkasing	Independent Director	3.2yrs	SEK 150.00k	geen gegevens

7.7yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SCIB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

SciBase Holding Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

SciBase Holding AB (publ), Annual General Meeting, May 21, 2025

SciBase Holding AB (publ) Appoints Leda Beaty as Head of US Commercial Operations

SciBase Holding AB (publ), Annual General Meeting, May 17, 2024

SciBase Holding AB (publ) Appoints Nomination Committee

Chairman & Interim CEO recently bought kr534k worth of stock

Scibase Appoints Pia Renaudin as Chief Executive Officer

Recent updates

SciBase Holding AB (publ), Annual General Meeting, May 21, 2025

Consensus EPS estimates fall by 14%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 67% to kr2.80

New major risk - Share price stability

SciBase Holding AB (publ) Appoints Leda Beaty as Head of US Commercial Operations

Consensus EPS estimates upgraded to kr0.22 loss, revenue downgraded

New minor risk - Profitability

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Shareholder dilution

Scibase Announces the Launch of Ebarrier Score, the First Ai-Driven Skin Barrier Assessment Tool for Research and Cosmetic Testing

New minor risk - Shareholder dilution

Price target decreased by 13% to kr1.68

SciBase Holding AB (publ) has completed a Composite Units Offering.

Consensus EPS estimates upgraded to kr0.27 loss

Consensus revenue estimates fall by 11%

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 39% to kr4.30

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

SciBase Holding AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024

SciBase Holding AB (publ) to Report Q1, 2024 Results on May 09, 2024

SciBase Holding AB (publ), Annual General Meeting, May 17, 2024

SciBase Holding AB (publ) Appoints Nomination Committee

New major risk - Market cap size

SciBase Holding AB Announces the Publication of A Collaborative Scientific Project with the Swiss Institute of Allergy and Asthma Research in Davos, Switzerland

Chairman & Interim CEO recently bought kr534k worth of stock

Scibase Appoints Pia Renaudin as Chief Executive Officer

Consensus EPS estimates fall by 33%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

SciBase Holding AB (publ) Announces Executive Changes

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.30 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

SciBase Holding AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

Price target decreased to kr11.00

SciBase Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

SciBase Holding AB (publ) Announces New Study Shows Nevisense Significantly Improves US Clinician's Decision-Making Beyond Dermoscopy

SciBase Holding AB (publ), Annual General Meeting, May 18, 2023

Is SciBase Holding (STO:SCIB) In A Good Position To Deliver On Growth Plans?

SciBase Holding AB Announces Nevisense Detects Skin Barrier Damage in Mice Caused by Household Detergents

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SciBase Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

SciBase Holding AB (publ) Announces US Study Shows That EIS and Nevisense Significantly Improves Clinicians' Diagnostic Accuracy

Will SciBase Holding (STO:SCIB) Spend Its Cash Wisely?

SciBase Holding AB (publ) Study Shows Clinical Benefit of Nevisense

Full year 2021 earnings released: kr0.67 loss per share (vs kr1.12 loss in FY 2020)

CEO & President recently bought kr76k worth of stock

Independent Chairman recently bought kr504k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Financial Officer recently bought kr111k worth of stock

Third quarter 2021 earnings released: kr0.13 loss per share (vs kr0.20 loss in 3Q 2020)

We're Hopeful That SciBase Holding (STO:SCIB) Will Use Its Cash Wisely

Second quarter 2021 earnings released: kr0.19 loss per share (vs kr0.38 loss in 2Q 2020)

SciBase Holding AB (publ) announced that it has received SEK 71.214109 million in funding from Van Herk Investments B.V., Ostvast Capital Management Limited, and other investors

First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.54 loss in 1Q 2020)

Scibase Receives Important European MDR Certification

SciBase Holding AB (publ) Submits First Reimbursement Application to CMS in Florida

Is SciBase Holding (STO:SCIB) In A Good Position To Deliver On Growth Plans?

David Melin Resigns as Head of Product Development of SciBase AB

Full year 2020 earnings released: kr1.12 loss per share (vs kr2.38 loss in FY 2019)

Revenue beats expectations

SciBase Holding AB (publ) to Report Q3, 2021 Results on Nov 11, 2021

Calculating The Intrinsic Value Of SciBase Holding AB (publ) (STO:SCIB)

SciBase Holding AB (publ) Announces New Study Published Validating Further Nevisense Indication, Non-Melanoma Skin Cancer

New 90-day high: kr4.85

Third quarter 2020 earnings released: kr0.20 loss per share

SciBase Holding AB (publ) to Report Fiscal Year 2020 Results on Feb 19, 2021